100,000-Person study pits Weight-Loss drugs against heart attacks
NCT ID NCT07619508
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study compares two popular weight-loss medications, tirzepatide and semaglutide, in 100,000 adults who are overweight or obese and at risk for heart problems but do not have diabetes. Researchers are analyzing real-world data to see which drug better prevents death, heart attacks, or strokes. The goal is to guide doctors in choosing the best treatment for heart health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?